FIELD: immunology.
SUBSTANCE: disclosed is a T cell comprising a chimeric antigen receptor (CAR) and a chimeric costimulatory receptor (CCR), as well as a method of producing said cell. There are described methods of inducing tumor cell death, treating and preventing neoplasm, a pharmaceutical composition and a kit for immunotherapy.
EFFECT: chimeric costimulatory receptor binding with antigen provides costimulatory signal delivery to T-cell that provides higher degree of cytolytic activity.
51 cl, 6 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2729118C2 |
| CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES | 2019 |
|
RU2824391C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
| COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND | 2018 |
|
RU2777911C2 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
